Showing results (891-900 of 5,983) with videos related to
Sort By:
Pageof 599
Molecular Cancer Therapeutics|May 7, 2009
Cell surface profiling with peptide libraries yields ligand arrays that classify breast tumor subtypesKaren Y Dane, Claudia Gottstein, Patrick S DaughertyMolecular Cancer Therapeutics|May 7, 2009
Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluationJie Jin, Hui Liu, Chunmei Yang, et al.Molecular Cancer Therapeutics|May 7, 2009
A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicityYang Feng, Xiaodong Xiao, Zhongyu Zhu, et al.Molecular Cancer Therapeutics|May 21, 2010
Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone modelJoy C Yang, Lanfang Bai, Stanley Yap, et al.Molecular Cancer Therapeutics|August 25, 2006
Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivityElizabeth Buck, Alexandra Eyzaguirre, John D Haley, et al.Molecular Cancer Therapeutics|August 25, 2006
Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of actionBryan Husbeck, Rumi S Bhattacharyya, David Feldman, et al.Molecular Cancer Therapeutics|August 25, 2006
Development of engineered antibodies specific for the Müllerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancerQing-an Yuan, Heidi H Simmons, Matthew K Robinson, et al.Molecular Cancer Therapeutics|August 25, 2006
Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapyHui Wang, Elizabeth R Rayburn, Wei Wang, et al.Molecular Cancer Therapeutics|September 21, 2006
Therapeutic value of glycosaminoglycans in cancerGeorge W Yip, Martin Smollich, Martin GötteMolecular Cancer Therapeutics|September 21, 2006
The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor modelsHan Ying, Sandra L Biroc, Wei-Wei Li, et al.Pageof 599